Patents by Inventor Ingo Röhl

Ingo Röhl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10711298
    Abstract: The invention relates to a method for the detection of oligonucleotides using anion exchange high performance liquid chromatography. Fluorescently labelled peptide nucleic acid oligomers, complementary to the oligonucleotide are hybridized to the oligonucleotides. Anion exchange high performance liquid chromatography is then performed and the hybridized moieties detected and quantitated. The invention also relates to a method for the simultaneous detection of both strands of an oligonucleotide in parallel from one sample, and a kit for use in qualitative and quantitative detection of one or two strands of an oligonucleotide.
    Type: Grant
    Filed: October 6, 2009
    Date of Patent: July 14, 2020
    Assignee: AXOLABS GMBH
    Inventors: Ingo Roehl, Markus Schuster, Stephan Seiffert
  • Patent number: 10400269
    Abstract: Provided herein is a method for detecting at least two distinct oligonucleotides of equal length in parallel from one biological sample, comprising the steps of providing a biological sample containing or suspected of containing oligonucleotides of interest; forming a hybridization mixture using at least two fluorescently labelled detection molecules with different surface charges; separating the detection molecules hybridized to the oligonucleotides by anion exchange HPLC; and detecting the hybridized detection molecule-oligonucleotide moieties by quantitative fluorescence readout. In a further aspect, a kit comprising at least two detection molecules is provided. In another aspect, provided herein is the use of at least two detection molecules with different surface charges for quantitatively detecting at least two distinct oligonucleotides of equal length in parallel from one biological sample.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: September 3, 2019
    Assignee: AXOLABS GMBH
    Inventors: Ingo Röhl, Nadine Dörfler, Julia Knis
  • Publication number: 20180312909
    Abstract: The invention relates to a method for the detection of oligonucleotides using anion exchange high performance liquid chromatography. Fluorescently labelled peptide nucleic acid oligomers, complementary to the oligonucleotide are hybridized to the oligonucleotides. Anion exchange high performance liquid chromatography is then performed and the hybridized moieties detected and quantitated. The invention also relates to a method for the simultaneous detection of both strands of an oligonucleotide in parallel from one sample, and a kit for use in qualitative and quantitative detection of one or two strands of an oligonucleotide.
    Type: Application
    Filed: May 7, 2018
    Publication date: November 1, 2018
    Inventors: Ingo ROEHL, Markus SCHUSTER, Stephan SEIFFERT
  • Patent number: 9968647
    Abstract: The invention provides novel compounds and conjugates of these compounds useful for the delivery of biologically active substances. Further novel design criteria for chemically stabilized siRNA particular useful when covalently attached to a delivery polymer to achieve in vivo mRNA knock down are disclosed therein.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: May 15, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Philipp Hadwiger, Torsten Hoffmann, Kerstin Jahn-Hofmann, Eric A. Kitas, David L. Lewis, Peter Mohr, Hans Martin Mueller, Guenther Ott, Ingo Roehl, David B. Rozema
  • Publication number: 20180073060
    Abstract: In a first aspect, the invention relates to a method for detecting at least two distinct oligonucleotides of equal length in parallel from one biological sample, said method comprising the steps of providing a biological sample containing or suspected of containing said oligonucleotides of interest; forming a hybridization mixture using at least two fluorescently labelled detection molecules with different surface charges; separating the detection molecules hybridised to said oligonucleotides by anion exchange HPLC; and detecting the hybridized detection molecule-oligonucleotide moieties by means of quantitative fluorescence readout. In a further aspect, the invention relates to a kit comprising at least two detection molecules as defined in the present invention. In another aspect, the invention relates to the use of at least two detection molecules with different surface charges for quantitatively detecting at least two distinct oligonucleotides of equal length in parallel from one biological sample.
    Type: Application
    Filed: March 2, 2016
    Publication date: March 15, 2018
    Inventors: Ingo ROEHL, Nadine DÖRFLER, Julia KINS
  • Patent number: 9796756
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cell in vivo. The pharmacokinetic modulator improve in vivo targeting compared to the targeting ligand alone. Targeting ligand-pharmacokinetic modulator targeting moiety targeted RNAi polynucleotides can be administered in vivo alone or together with co-targeted delivery polymers.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: October 24, 2017
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Philipp Hadwiger, Torsten Hoffmann, Eric A Kitas, Peter Mohr, Ingo Roehl, Linda Valis, David B Rozema, David L Lewis, Darren H Wakefield
  • Publication number: 20170022505
    Abstract: The invention provides novel compounds and conjugates of these compounds useful for the delivery of biologically active substances. Further novel design criteria for chemically stabilized siRNA particular useful when covalently attached to a delivery polymer to achieve in vivo mRNA knock down are disclosed therein.
    Type: Application
    Filed: April 4, 2016
    Publication date: January 26, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Philipp Hadwiger, Torsten Hoffmann, Kerstin Jahn-Hofmann, Eric A. Kitas, David L. Lewis, Peter Mohr, Hans Martin Mueller, Guenther Ott, Ingo Roehl, David B. Rozema
  • Publication number: 20160102120
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cell in vivo. The pharmacokinetic modulator improve in vivo targeting compared to the targeting ligand alone. Targeting ligand-pharmacokinetic modulator targeting moiety targeted RNAi polynucleotides can be administered in vivo alone or together with co-targeted delivery polymers.
    Type: Application
    Filed: December 17, 2015
    Publication date: April 14, 2016
    Inventors: Philipp Hadwiger, Torsten Hoffmann, Eric A Kitas, Peter Mohr, Ingo Roehl, Linda Valis, David B Rozema, David L Lewis, Darren H Wakefield
  • Patent number: 9301990
    Abstract: The invention provides novel compounds and conjugates of these compounds useful for the delivery of biologically active substances. Further novel design criteria for chemically stabilized siRNA particular useful when covalently attached to a delivery polymer to achieve in vivo mRNA knock down are disclosed therein.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: April 5, 2016
    Assignee: HOFFMANN-LA ROCHE, INC.
    Inventors: Philipp Hadwiger, Torsten Hoffmann, Kerstin Jahn-Hofmann, Eric A. Kitas, David L. Lewis, Peter Mohr, Hans Martin Mueller, Guenther Ott, Ingo Roehl, David B. Rozema
  • Publication number: 20160032273
    Abstract: The present invention describes methods for the characterization of mRNA molecules during mRNA production. Characterizing mRNA includes processes such as oligonucleotide mapping, reverse transcriptase sequencing, charge distribution analysis, and detection of RNA impurities. Oligonucleotide mapping includes using an RNase to digest antisense duplexes from an RNA transcript, and then subjecting the digested RNA to reverse phase HPLC, anion exchange HPLC, and/or mass spectrometry analysis. Reverse transcriptase sequencing involves reverse transcription of an RNA transcript followed by DNA sequencing. Charge distribution analysis can comprise procedures such as anion exchange HPLC, or capillary electrophoresis. Detection of impurities includes detecting short mRNA transcripts, RNA-RNA hybrids, and RNA-DNA hybrids.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Inventors: Zahra SHAHROKH, Ingo RÖHL, Vlad Boris SPIVAK, Tirtha CHAKRABORTY, John Grant AUNINS
  • Patent number: 9249179
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cell in vivo. The pharmacokinetic modulator improve in vivo targeting compared to the targeting ligand alone. Targeting ligand-pharmacokinetic modulator targeting moiety targeted RNAi polynucleotides can be administered in vivo alone or together with co-targeted delivery polymers.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: February 2, 2016
    Assignee: Arrowhead Madison Inc.
    Inventors: Philipp Hadwiger, Torsten Hoffmann, Eric A. Kitas, Peter Mohr, Ingo Roehl, Linda Valis, David B. Rozema, David L. Lewis, Darren H. Wakefield
  • Patent number: 9198947
    Abstract: The invention provides use of novel compounds for delivery of nucleic acids, and conjugates of these compounds with nucleic acids. Further novel design criteria for chemically stabilized siRNA particular useful when covalently attached to said compounds and co-administered with a delivery polymer to achieve mRNA knock down in vivo are disclosed therein.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: December 1, 2015
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Philipp Hadwiger, Torsten Hoffmann, Kerstin Jahn-Hofmann, Eric A. Kitas, David L. Lewis, Peter Mohr, Hans Martin Mueller, Guenther Ott, Ingo Roehl, David B. Rozema
  • Patent number: 9107957
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted melittin delivery peptides. Delivery peptides provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery peptides.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: August 18, 2015
    Assignee: Arrowhead Madison Inc.
    Inventors: David B Rozema, David L Lewis, Darren Wakefield, Eric Kitas, Philipp Hadwiger, Jon Wolff, Ingo Röhl, Peter Mohr, Torsten Hoffmann, Kerstin Jahn-Hofmann, Hans Martin Mueller, Günther Ott, Andrei V Blokhin, Jonathan D Benson, Jeffrey C Carlson
  • Patent number: 8993746
    Abstract: This invention relates to modified double-stranded oligoribonucleic acid (dsRNA) having improved stability in cells and biological fluids, and methods of making and identifying dsRNA having improved stability, and of using the dsRNA to inhibit the expression or function of a target gene.
    Type: Grant
    Filed: March 27, 2012
    Date of Patent: March 31, 2015
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Hans-Peter Vornlocher, Ingo Roehl, Philipp Hadwiger, Tracy Stage Zimmermann, Muthiah Manoharan, Kallanthottathil G. Rajeev, Akin Akinc
  • Patent number: 8802773
    Abstract: The present invention is directed compositions for delivery of RNA interference (RNAi) polynucleotides to cells in vivo. The compositions comprise amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate or DPC) are further covalently linked to an RNAi polynucleotide or co-administered with a targeted RNAi polynucleotide-targeting molecule conjugate.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 12, 2014
    Assignee: Arrowhead Madison Inc.
    Inventors: David B Rozema, David L Lewis, Darren H Wakefield, Eric A Kitas, Philipp Hadwiger, Jon A Wolff, Ingo Roehl, Peter Mohr, Torsten Hoffmann, Kerstin Jahn-Hofmann, Hans Martin Mueller, Guenther Ott, Andrei V Blokhin, Jeffrey C Carlson, Jonathan D Benson
  • Publication number: 20140135380
    Abstract: The invention provides use of novel compounds for delivery of nucleic acids, and conjugates of these compounds with nucleic acids. Further novel design criteria for chemically stabilized siRNA particular useful when covalently attached to said compounds and co-administered with a delivery polymer to achieve mRNA knock down in vivo are disclosed therein.
    Type: Application
    Filed: June 13, 2013
    Publication date: May 15, 2014
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Philipp Hadwiger, Torsten Hoffmann, Kerstin Jahn-Hofmann, Eric A. Kitas, David L. Lewis, Peter Mohr, Hans Martin Mueller, Guenther Ott, Ingo Roehl, David B. Rozema
  • Publication number: 20140135381
    Abstract: The invention provides novel compounds and conjugates of these compounds useful for the delivery of biologically active substances. Further novel design criteria for chemically stabilized siRNA particular useful when covalently attached to a delivery polymer to achieve in vivo mRNA knock down are disclosed therein.
    Type: Application
    Filed: June 13, 2013
    Publication date: May 15, 2014
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Philipp Hadwiger, Torsten Hoffmann, Kerstin Jahn-Hofmann, Eric A. Kitas, David L. Lewis, Peter Mohr, Hans Martin Mueller, Guenther Ott, Ingo Roehl, David B. Rozema
  • Publication number: 20130281658
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted melittin delivery peptides. Delivery peptides provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery peptides.
    Type: Application
    Filed: June 25, 2013
    Publication date: October 24, 2013
    Inventors: David B Rozema, David L Lewis, Darren Wakefield, Eric Kitas, Philipp Hadwiger, Jon Wolff, Ingo Röhl, Peter Mohr, Torsten Hoffmann, Kerstin Jahn-Hofmann, Hans Martin Mueller, Günther Ott, Andrei V Blokhin, Jonathan D Benson, Jeffrey C Carlson
  • Patent number: 8501930
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted melittin delivery peptides. Delivery peptides provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery peptides.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: August 6, 2013
    Assignee: Arrowhead Madison Inc.
    Inventors: David B. Rozema, Darren H. Wakefield, David L. Lewis, Jon A. Wolff, Andrei V. Blokhin, Jonathan D. Benson, Jeffrey C. Carlson, Philipp Hadwiger, Eric A. Kitas, Torsten Hoffmann, Kerstin Jahn-Hofmann, Peter Mohr, Hans Martin Mueller, Guenther Ott, Ingo Roehl
  • Publication number: 20130190484
    Abstract: The present invention is directed compositions for delivery of RNA interference (RNAi) polynucleotides to cells in vivo. The compositions comprise amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate or DPC) are further covalently linked to an RNAi polynucleotide or co-administered with a targeted RNAi polynucleotide-targeting molecule conjugate.
    Type: Application
    Filed: March 15, 2013
    Publication date: July 25, 2013
    Applicant: ARROWHEAD MADISON INC.
    Inventors: David Rozema, David Lewis, Darren Wakefield, Eric Kitas, Philipp Hadwiger, Jon Wolff, Ingo Roehl, Peter Mohr, Torsten Hoffmann, Kerstin Jahn-Hofmann, Hans Martin Mueller, Guenther Ott, Andrei Blokhin, Jeffrey Carlson, Jonathan Benson